FDA approved Lamictal in the form of extended release tablets for the treatment of generalized tonic-clonic seizures

US Food and Drug Administration (FDA) approved the extension of lamotrigine indications in the form of extended-release tablets (Lamictal made by GlaxoSmithKline) as adjuvant treatment of generalized tonic-clonic seizures once daily in patients aged 13 years and older .

FDA decision is based on the results of a double-blind multi-center clinical trial lasting 19 weeks which involved 143 patients.

The study showed that using of Lamictal in the form of extended release tablets as adjunctive therapy in combination with other anti-epileptic drugs can significantly reduce the number and frequency of seizures.

The most common Lamictal side effects include: headache, nausea, vomiting, fever and rash. The medication is contraindicated in simultaneous use with valproats.